XML 24 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue from contracts with customers
 3 Months Ended
Mar. 31, 2025
Revenue from contracts with customers
NOTE 3 – Revenue from contracts with customers:
Disaggregation of revenue
The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15.
 
    
Three months ended March 31, 2025
  
    
United States
     
Europe
    
International
Markets
     
Other activities
     
Total
  
    
(U.S.$ in millions)
  
Sale of goods
      1,514        1,198       553        129        3,395  
Licensing arrangements
      22        7       6        1        36  
Distribution
      373        §       11        —         384  
Other
      1        (12 )      12        76        76  
  
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
   $ 1,910      $ 1,194     $ 582      $ 206      $ 3,891  
  
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
 
§
Represents an amount less than $0.5 million.
 
    
Three months ended March 31, 2024
  
    
United States
     
Europe
     
International
Markets
     
Other activities
     
Total
  
    
(U.S.$ in millions)
  
Sale of goods
      1,321        1,252        566        128        3,267  
Licensing arrangements
      23        11        5        §        40  
Distribution
      381        §        9        —         391  
Other
      §        9        16        97        121  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
   $ 1,725      $ 1,272      $ 597      $ 225      $ 3,819  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
 
§
Represents an amount less than $0.5 million.
Variable consideration
Variable consideration mainly includes sales reserves and allowances (“SR&A”), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables.
The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions.
 
 
SR&A to U.S. customers comprised approximately 68% of the Company’s total SR&A as of March 31, 2025, with the remaining balance primarily related to customers in Canada and Germany. The changes in SR&A for third-party sales for the three months ended March 31, 2025 and 2024 were as follows:
 
    
Sales Reserves and Allowances
        
    
Reserves
included in
Accounts
Receivable, net
    
Rebates
    
Medicaid and
other
governmental
allowances
    
Chargebacks
    
Returns
    
Other
    
Total reserves
included in
Sales Reserves
and
Allowances
    
Total
  
    
(U.S.$ in millions)
  
Balance at January 1, 2025
    $ 56     $ 1,674     $ 561     $ 936     $ 399     $ 108     $ 3,678     $ 3,734  
Provisions related to sales made in current year period
      99       1,250       219       1,988       69       30       3,556       3,655  
Provisions related to sales made in prior periods
      —        (37 )      9       (20 )      (3 )      (4 )      (55 )      (55 ) 
Credits and payments
      (83 )      (1,224 )      (193 )      (2,035 )      (55 )      (16 )      (3,523 )      (3,606 ) 
Translation differences
      —        19       5       6       2       8       40       40  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance at March 31, 2025
    $ 72     $ 1,682     $ 601     $ 875     $ 412     $ 126     $ 3,696     $ 3,768  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
 
    
Sales Reserves and Allowances
        
    
Reserves
included in
Accounts
Receivable, net
    
Rebates
    
Medicaid and
other
governmental
allowances
    
Chargebacks
    
Returns
    
Other
    
Total reserves
included in
Sales Reserves
and
Allowances
    
Total
  
    
(U.S.$ in millions)
  
Balance at January 1, 2024
    $ 61     $ 1,603     $ 540     $ 859     $ 436     $ 97     $ 3,535     $ 3,596  
Provisions related to sales made in current year period
      93       1,118       181       1,942       73       40       3,354       3,447  
Provisions related to sales made in prior periods
      —        10       20       (11 )      (6 )      (1 )      12       12  
Credits and payments
      (87 )      (1,086 )      (171 )      (1,935 )      (67 )      (18 )      (3,277 )      (3,364 ) 
Translation differences
      —        (17 )      (3 )      (5 )      (3 )      (2 )      (30 )      (30 ) 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance at March 31, 2024
    $ 67     $ 1,628     $ 567     $ 850     $ 433     $ 116     $ 3,594     $ 3,661